(Q33394863)

26 July 2017

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors (English)

1 reference

26 July 2017

2

Kiyohiko Hatake

1 reference

26 July 2017

Akira Fukutomi

1

1 reference

26 July 2017

Kaoru Matsui

3

1 reference

26 July 2017

Sakura Sakajiri

4

1 reference

26 July 2017

Tomonori Hirashima

5

1 reference

26 July 2017

Hiromi Tanii

6

1 reference

26 July 2017

Ken Kobayashi

7

1 reference

26 July 2017

Nobuyuki Yamamoto

8

1 reference

26 July 2017

12 April 2011

1 reference

Investigational New Drugs

26 July 2017

1 reference

26 July 2017

30

1 reference

26 July 2017

3

1 reference

26 July 2017

1096-1106

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-011-9666-9

26 July 2017

0 references

cites work

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Mechanisms of HDAC inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9666-9

Challenges of evaluating the cardiac effects of anticancer agents

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21484248

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9666-9

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference